Mesoblast (ASX:MSB) received seven years of orphan-drug exclusive approval from the US Food and Drug Administration for Ryoncil for the treatment of steroid-refractory acute graft versus host disease in pediatric patients aged two months and older, according to a Wednesday Australian bourse filing.
The period of statutory exclusivity means that the regulator will not approve another mesenchymal stromal or stem cell product for this indication for seven years from the approval of Ryoncil, the filing said.
Separately, Mesoblast has biologic exclusivity preventing another sponsor from referencing the Ryoncil biologic license application until December 2036.
Mesoblast's shares fell past 1% in recent trading on Thursday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。